Adaptimmune Therapeutics plc ADAP
Nov 21, 2025, 9:30 AM EST
52-week range unavailable
- YTD
- -91.00%
- 1 year
- -93.42%
- Market cap
- 75.16M
- Revenue (ttm)
- 141.46M
- Profit margin
- -51.25%
- Shares out
- 255.88M
- Forward P/E
- -1.52
- YTD return
- -91.00%
- 1-year return
- -93.42%
- Volume
- 1.68M
- Open
- 0.0425
- Previous close
- 0.0485
- Day's range
- 0.0425 – 0.0599
- Beta
- 2.25
- Price target
- 2.27 (+4573.5%)
2Y -0.5011 (-90.29%)
Key statistics
- Enterprise value
- 739.74M
- PEG ratio
- 0.00
- Price / sales
- 1.05
- Price / book
- 3.33
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 2399.60%
- Free cash flow
- -7.95M
- Total cash
- 214.79M
- Total debt
- 47.35M
- Return on equity
- -65.04%
- Short % of float
- 3.14%
- 50-day average
- 0.71418
- 200-day average
- 1.03
Analyst view
- Target (low)
- 1.00
- Target (mean)
- 2.27
- Target (high)
- 3.50
- Strong buy2
- Buy4
- Hold2
- Sell0
- Strong sell1
Next earnings
Consensus EPS estimate -0.154.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 13, 2024 | Sep 1, 2024 | -0.17 | -0.07 | +0.10 | +58.82% |
| Aug 12, 2024 | Jun 1, 2024 | 0.00 | 0.27 | — | — |
| May 15, 2024 | Mar 1, 2024 | -0.16 | -0.18 | -0.02 | -12.50% |
| Mar 6, 2024 | Dec 1, 2023 | -0.12 | -0.24 | -0.12 | -100.00% |
| Nov 8, 2023 | Sep 1, 2023 | -0.20 | -0.20 | 0.00 | 0.00% |
| Aug 9, 2023 | Jun 1, 2023 | -0.17 | -0.21 | -0.04 | -23.53% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 27, 2024 | Mizuho | main | Outperform | Outperform |
| Nov 19, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Nov 15, 2024 | Guggenheim | main | Buy | Buy |
| Nov 14, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Aug 13, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 5, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
About Adaptimmune Therapeutics plc
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United Kingdom
- Website
- adaptimmune.com
News
No recent headlines
Headlines appear here as they are published.
Your note
Sign in to keep a note on ADAP — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BERTRAND WILLIAM C JR | Chief Operating Officer | Sale | Jan 16, 2024 | 20,201 |
| LUNGER JOHN | Officer | Sale | Jan 16, 2024 | 19,015 |
| MENZEL GARRY E | Director | Sale | Jul 9, 2023 | 75,056 |
| NORRY ELLIOT | Officer | Sale | Jan 16, 2024 | 19,257 |
| PICCINA CINTIA | Officer | Sale | Jun 17, 2024 | 38,293 |
| RAWCLIFFE ADRIAN | Chief Executive Officer | Sale | Jan 16, 2024 | 44,848 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Matrix Capital Management | 14.73% | 37,681,515 | 21.81M | Sep 29, 2024 |
| EcoR1 Capital, LLC | 10.71% | 27,404,070 | 15.86M | Sep 29, 2024 |
| NEA Management Company, LLC | 6.67% | 17,079,778 | 9.89M | Sep 29, 2024 |
| Baillie Gifford and Company | 6.56% | 16,775,860 | 9.71M | Sep 29, 2024 |
| Long Focus Capital Management, LLC | 5.20% | 13,299,890 | 7.70M | Sep 29, 2024 |
| Pfm Health Sciences, Lp | 3.91% | 10,000,787 | 5.79M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| SPDR Portfolio Developed World ex-US ETF | 0.10% | 246,307 | 142.56K | Sep 29, 2024 |
| SPDR (R) Idx Shares-SPDR (R) S&P (R) International Small Cap ETF | 0.06% | 148,385 | 85.89K | Sep 29, 2024 |
| Fidelity Enhanced Small Cap ETF | 0.06% | 161,545 | 93.50K | Oct 30, 2024 |
| Fidelity NASDAQ Composite Index Fund | 0.05% | 139,801 | 80.92K | Oct 30, 2024 |
| Trust for Professional Managers-ActivePassive International Equity ETF | 0.02% | 44,364 | 25.68K | Aug 30, 2024 |
| Northern Small Cap Core Fund | 0.01% | 16,891 | 9.78K | Sep 29, 2024 |